

Matilda Florentin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2459568/publications.pdf>

Version: 2024-02-01

31
papers

660
citations

687220

13
h-index

580701

25
g-index

31
all docs

31
docs citations

31
times ranked

871
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple actions of high-density lipoprotein. <i>Current Opinion in Cardiology</i> , 2008, 23, 370-378.	0.8	180
2	Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?. <i>Current Vascular Pharmacology</i> , 2010, 8, 720-730.	0.8	53
3	Proton pump inhibitor-induced hypomagnesemia: A new challenge. <i>World Journal of Nephrology</i> , 2012, 1, 151.	0.8	42
4	Vitamin D and Metabolic Syndrome: Is There a Link?. <i>Current Pharmaceutical Design</i> , 2010, 16, 3417-3434.	0.9	36
5	Bone Health in Patients with Dyslipidemias: An Underestimated Aspect. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1639.	1.8	34
6	Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation. <i>Current Vascular Pharmacology</i> , 2011, 9, 385-400.	0.8	32
7	The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2011, 27, 685-692.	0.9	31
8	Simvastatin interactions with other drugs. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 439-444.	1.0	29
9	Drug-Induced Hypophosphatemia: Current Insights. <i>Drug Safety</i> , 2020, 43, 197-210.	1.4	28
10	Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia. <i>Current Vascular Pharmacology</i> , 2010, 8, 820-830.	0.8	27
11	The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. <i>Archives of Medical Science</i> , 2012, 3, 437-443.	0.4	23
12	An overview of diagnosis and management of drug-induced hypomagnesemia. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00829.	1.1	21
13	Emerging options in the treatment of dyslipidemias: a bright future?. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 247-270.	1.0	14
14	Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. <i>World Journal of Diabetes</i> , 2022, 13, 85-96.	1.3	14
15	Colonoscopy preparation-induced disorders in renal function and electrolytes. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 50.	0.6	13
16	Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 107-120.	0.9	10
17	Hyponatremia in Patients with Hematologic Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 3721.	1.0	10
18	Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 274-282.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Effects of Rimobabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study. <i>Angiology</i> , 2010, 61, 365-371.	0.8	9
20	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 739-755.	0.8	8
21	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <i>Lipids in Health and Disease</i> , 2020, 19, 114.	1.2	6
22	Emerging drugs for hyperlipidaemia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 471-488.	1.0	5
23	Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report. <i>Current Drug Safety</i> , 2019, 14, 238-241.	0.3	5
24	Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries. <i>Current Pharmaceutical Design</i> , 2019, 24, 3605-3615.	0.9	5
25	Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102979.	2.0	5
26	No effect of fenugreek, bergamot and olive leaf extract on glucose homeostasis in patients with prediabetes: a randomized double-blind placebo-controlled study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2019, 4, 162-166.	0.5	4
27	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5366.	1.0	4
28	Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke. <i>Drug Safety</i> , 2017, 40, 851-853.	1.4	2
29	Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 42.	0.8	1
30	Hyperemesis Gravidarum: A Benign Condition of Pregnancy or a Challenging Metabolic Disorder?. <i>European Journal of Case Reports in Internal Medicine</i> , 2020, 7, 001979.	0.2	0
31	Hyperemesis Gravidarum: A Benign Condition of Pregnancy or a Challenging Metabolic Disorder?. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 7, 001979.	0.2	0